Page last updated: 2024-11-06

bezafibrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Bezafibrate is a fibrate medication used to treat high cholesterol and triglycerides. It is a synthetic derivative of fibric acid and acts as a peroxisome proliferator-activated receptor alpha (PPARα) agonist. Bezafibrate promotes the breakdown of lipids and reduces the production of cholesterol and triglycerides in the liver. Its synthesis involves a multi-step process starting with the reaction of 2-chloro-4-nitrobenzoyl chloride with 2,4-dihydroxybenzoic acid to form the intermediate, followed by reduction of the nitro group to an amine and reaction with ethyl chloroacetate. Bezafibrate is primarily studied for its effects on lipid metabolism and its potential benefits in treating dyslipidemia, a condition characterized by high cholesterol and triglycerides. Research indicates that it can reduce the risk of cardiovascular disease by lowering LDL cholesterol levels and raising HDL cholesterol levels. However, bezafibrate can also have side effects such as liver problems, gastrointestinal disturbances, and muscle pain.'

Cross-References

ID SourceID
PubMed CID39042
CHEMBL ID264374
CHEBI ID47612
SCHEMBL ID16299
MeSH IDM0002449

Synonyms (214)

Synonym
AC-6817
MLS001148205
AB00052265-15
BRD-K46018455-001-06-0
gtpl2668
KBIO1_000092
DIVK1C_000092
bezatol
bezalip retard
bezalip sr
cedur
befizal
bezalip
bm-15075
SPECTRUM_001443
BSPBIO_003119
IDI1_000092
brn 4267656
propionic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-
bm 15075
ccris 9085
bezafibratum [inn-latin]
bezafibrato [inn-spanish]
bf-759
bezafibrat
propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-
einecs 255-567-9
bezafibrato [spanish]
bm-15.075
lo 44
PRESTWICK_724
bezafibrate ,
41859-67-0
BIO2_000514
BIO2_000034
cas-41859-67-0
NCGC00016850-01
PRESTWICK3_000378
PRESTWICK2_000378
BSPBIO_000535
IDI1_033784
BSPBIO_001314
SPECTRUM5_001967
AB00052265
bdbm28701
chembl264374 ,
2-(4-{2-[(4-chlorophenyl)formamido]ethyl}phenoxy)-2-methylpropanoic acid
2-[p-[2-p-chlorobenzamido)ethyl]phenoxy]-2-methylpropionic acid
PEM ,
bezafibrate, >=98%, solid
DB01393
bezatol sr (tn)
bezafibrate (jp17/usan/inn)
D01366
SPECTRUM5_001079
NCGC00023317-07
2-(p-(2-(p-chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid
NCGC00023317-04
NCGC00023317-06
NCGC00023317-05
CHEBI:47612 ,
bezafibratum
2-{4-[2-(4-chlorobenzamido)ethyl]phenoxy}-2-methylpropanoic acid
NCGC00023317-03
bezafibrato
MLS000028533 ,
smr000058298
KBIOGR_000669
KBIO3_002619
KBIO2_007059
KBIO3_000068
KBIOSS_001923
KBIO2_005170
KBIO2_001923
KBIOSS_000034
KBIO2_002602
KBIO2_004491
KBIOGR_000034
KBIO3_000067
KBIO2_000034
PRESTWICK0_000378
SPBIO_002456
NINDS_000092
SPECTRUM4_000325
SPECTRUM3_001500
SPBIO_000824
PRESTWICK1_000378
SPECTRUM2_000922
SPECTRUM1502046
BPBIO1_000589
NCGC00023317-08
NCGC00016850-02
solibay
reducterol
bezabeta
difaterol
beza-lande
2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid
bezafibrat pb
regadrin b
bezamerck
beza-puren
bm 15.075
durabezur
bezacur
lipox
sklerofibrat
eulitop
azufibrat
HMS2092B12
HMS2089F04
HMS1989B16
2-[4-[2-(4-chlorobenzamido)ethyl]phenoxy]isobutyric acid
B3346
NCGC00016850-11
bezatol sr
nsc-758174
2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid
HMS1791B16
HMS500E14
HMS1361B16
AKOS005107743
HMS1569K17
HMS1921H16
HMS3261D21
HMS2096K17
tox21_301845
NCGC00255376-01
dtxcid909869
dtxsid3029869 ,
2-[4-[2-(4-chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid
pharmakon1600-01502046
BCP9000398
nsc758174
tox21_110645
HMS2233E22
S4159
CCG-39683
NCGC00016850-12
NCGC00016850-05
NCGC00016850-08
NCGC00016850-07
NCGC00016850-06
NCGC00016850-10
NCGC00016850-09
NCGC00016850-03
NCGC00016850-04
propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-
2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-propanoic acid
bezafibrate [usan:inn:ban:jan]
y9449q51xh ,
unii-y9449q51xh
nsc 758174
BCP0726000153
FT-0622617
LP00500
AB03023
bezafibrate [ep monograph]
bezafibrate [who-dd]
bezafibrate [inn]
bezafibrate [mart.]
bezafibrate [mi]
bezafibrate [jan]
bezafibrate [usan]
HMS3369B13
HY-B0637
SCHEMBL16299
NCGC00016850-15
tox21_110645_1
HS-0040
2-(4-(2-parachlorobenzamidoethyl)phenoxy)-2-methylpropionic acid
NCGC00261185-01
tox21_500500
W-106291
HMS3402B16
HMS3650K22
AB00052265_17
OPERA_ID_376
AB00052265_16
mfcd00078970
bezafibrate, european pharmacopoeia (ep) reference standard
bezafibrate, analytical reference material
bm15075
sr-01000000106
SR-01000000106-3
HMS3652M22
2-(4-(2-(4-chlorobenzamido)ethyl)phenoxy)-2-methylpropanoic acid
SR-01000000106-4
SR-01000000106-5
SBI-0051715.P002
HMS3713K17
SW196871-4
-2-methylpropanoic acid
2-(4-(2-(4-chlorobenzamido)ethyl)phenoxy)
2-[4-(2-{[(4-chlorophenyl)carbonyl]amino}ethyl)phenoxy]-2-methylpropanoic acid
BCP03700
Q577387
2-[4-[2-(4-chlorobezamide)ethyl]phenoxy]-2-methylpropanoic acid
bezafibrate,(s)
bezafibrate 100 microg/ml in acetonitrile
SR-01000000106-10
benafibrate
BRD-K46018455-001-17-7
SB17361
SDCCGSBI-0051715.P003
NCGC00016850-25
D70191
BB166159
EN300-18539646
bezafibratum (inn-latin)
bezafibrato (inn-spanish)
bezafibrate (ep monograph)
bezafibrate (mart.)
c10ab02

Research Excerpts

Overview

Bezafibrate (BZF) is an important member of the peroxisome proliferator-activated receptor (PPARs) family agonists, used in clinical practice as antihyperlipidemic. It is a BCS class II drug as it presents very low solubility in water; therefore, its bioavailability after oral administration is very poor.

ExcerptReferenceRelevance
"Bezafibrate (BZF) is an important member of the peroxisome proliferator-activated receptor (PPARs) family agonists, used in clinical practice as antihyperlipidemic."( Bezafibrate reduces the damage, activation and mechanical properties of lung fibroblast cells induced by hydrogen peroxide.
Adami, BS; Bastos, MS; Costa, BP; da Silva Melo, DA; de Oliveira, JR; de Sousa, AC; de Souza Basso, B; Dias, HB; Diz, FM; Donadio, MVF; Garcia, MCR; Haute, GV; Lima, KG; Luft, C; Matzenbacher, LS; Reghelin, CK; Rodrigues, KF; Xavier, LL, 2023
)
3.07
"Bezafibrate is a BCS class II drug as it presents very low solubility in water; therefore, its bioavailability after oral administration is very poor. "( Electrosprayed Polymeric Nanospheres for Enhanced Solubility, Dissolution Rate, Oral Bioavailability and Antihyperlipidemic Activity of Bezafibrate.
Anwer, K; Hussain, T; Khan, IU; Mehmood, Y; Mustapha, O; Shafique, S; Shahzad, Y; Shen, C; Sun, R; Yousaf, AM, 2020
)
2.2
"Bezafibrate (BF) is a widely used agent for hyperlipidemia that is also effective in ursodeoxycholic acid (UDCA)-resistant PBC patients."( Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation.
Harada, N; Hidaka, M; Inoue, Y; Iwasaki, S; Kawakita, T; Kawano, F; Kiyokawa, T; Matsui, T; Nagakura, S; Onishi, S; Saibara, T; Sakai, T; Takahashi, M; Takemoto, S, 2010
)
1.46
"Bezafibrate retard is a commonly used medication for hyperlipidemia."( Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan, R; Tur-Kaspa, R,
)
2.3
"Bezafibrate is a drug for dyslipidemia acting through peroxisome proliferator-activated receptors."( Usefulness of bezafibrate for ovulation induction in clomiphene citrate-resistant polycystic ovary syndrome patients with dyslipidemia: a prospective pilot study of seven cases.
Amita, M; Hara, S; Igarashi, H; Kurachi, H; Takahashi, T, 2010
)
1.44
"Bezafibrate is a widely used hypolipidemic agent and is known as a ligand of the peroxisome proliferator-activated receptors (PPARs). "( Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Hirayama, T; Honda, A; Ikegami, T; Imawari, M; Iwamoto, J; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Saito, Y; Takikawa, H, 2013
)
2.13
"Bezafibrate is a dual PPARs/PXR agonist with potent anticholestatic efficacy in early-stage PBC patients with an incomplete biochemical response to UDCA monotherapy."( Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Hirayama, T; Honda, A; Ikegami, T; Imawari, M; Iwamoto, J; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Saito, Y; Takikawa, H, 2013
)
2.13
"Bezafibrate is a known activator of peroxisome proliferator-activated receptors (PPARs) that can activate both PPARalpha and PPARbeta. "( Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice.
Aoyama, T; Burns, AM; Gonzalez, FJ; Peters, JM, 2003
)
3.2
"Bezafibrate is a hypolipidemic drug that belongs to the group of peroxisome proliferators because it binds to peroxisome proliferator-activated receptors type alpha (PPARs). "( Bezafibrate induces a mitochondrial derangement in human cell lines: a PPAR-independent mechanism for a peroxisome proliferator.
Bottoni, P; Castagnola, M; De Sole, P; Giardina, B; Maggiano, N; Martorana, GE; Messana, I; Nocca, G; Scatena, R; Vincenzoni, F, 2003
)
3.2
"Bezafibrate is a commonly used medicine for hyperlipidemia, and recently several reports have suggested the efficacy of bezafibrate for the treatment of primary biliary cirrhosis (PBC). "( Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.
Kimura, T; Kita, R; Kokuryu, H; Osaki, Y; Takamatsu, S; Tomono, N, 2006
)
3.22
"Bezafibrate (BZF) is a lipid regulator largely used for the treatment of hyperlipidaemia. "( Bezafibrate removal by means of ozonation: primary intermediates, kinetics, and toxicity assessment.
Andreozzi, R; Canterino, M; Dantas, RF; Esplugas, S; Marotta, R; Sans, C, 2007
)
3.23
"Bezafibrate is an effective hypolipidaemic agent, and its effect in moderate to severe uraemia is documented in this study."( The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia.
Baker, F; Walls, J; Williams, AJ, 1984
)
1.29
"Bezafibrate is a potent hypolipidemic agent, which causes marked proliferation of peroxisomes in rat liver. "( The short- and long-term effects of bezafibrate in the rat.
Fahimi, HD; Hartig, F; Ozel, M; Reinicke, A; Stegmeier, K; Sujatta, M; Yokota, S, 1982
)
1.98
"Bezafibrate is a potent lipid-lowering agent of the new generation."( Clinical experience with bezafibrate.
Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980
)
1.29
"Bezafibrate is a new lipid-lowering agent that quite constantly increases low HDL-cholesterol values in hyperlipoproteinaemic patients. "( Effects of bezafibrate on low HDL-cholesterol in patients with ischaemic cerebrovascular disease: a pilot study.
Kjellin, KG; Ledermann, H; Noring, L, 1981
)
2.1
"Bezafibrate is a new lipid-lowering agent with a more pronounced pharmacological effect, a different metabolism and a much shorter apparent half-life than clofibrate. "( Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
Kaufmann, B; Ledermann, H, 1981
)
1.97
"Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. "( Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 alpha-hydroxylase.
Angelin, B; Berglund, L; Einarsson, K; Reihnér, E; Rudling, M; Ståhlberg, D, 1995
)
2.1
"Bezafibrate is a latest generation fibrate derivative that substantially reduces total plasma cholesterol and triglyceride concentrations and increases high density lipoprotein (HDL) cholesterol. "( Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
Ericsson, CG, 1998
)
2.1
"Bezafibrate is a fibric acid derivative which has been widely used in the past 15 years. "( [Marked creatine-phosphokinase elevation in myopathy after treatment with bezafibrate].
Slobodin, G; Yeshurun, D, 2000
)
1.98
"Bezafibrate is an activator of peroxisome proliferator-activated receptors (PPAR) alpha. "( Effects of bezafibrate on beta-cell function of rat pancreatic islets.
Hashimoto, T; Nawata, H; Sako, Y; Tajiri, Y; Umeda, F; Yoshikawa, H, 2001
)
2.14
"Bezafibrate is a lipid-lowering drug, chemically related to clofibrate. "( Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.
Monk, JP; Todd, PA, 1987
)
3.16

Effects

Bezafibrate (BF) has been used to treat biliary damage, particularly in patients with primary biliary cirrhosis (PBC), and its clinical efficacy has been demonstrated. It has no effect on the incidence of coronary heart disease and of stroke combined but may reduce the incidence of non-fatal coronary events. BezAFibrate has effects on lipid metabolism and haemostatic function.

ExcerptReferenceRelevance
"and bezafibrate, which also has a lipid- and fibrinogen-lowering potency, was applied in patients suffering from cerebral multi-infarct dementia and disturbances of the hemorheologic situation."( [Hemorrheology and quality of life in fibrinogen- and lipid-lowering therapy].
Bertha, G; Freidl, W; Kleinert, G; Lechner, H; Schied, G; Walzl, B; Walzl, M, 1993
)
0.77
"Bezafibrate (BF) has been used to treat biliary damage, particularly in patients with primary biliary cirrhosis (PBC), and its clinical efficacy has been demonstrated. "( Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.
Enjoji, M; Fujino, T; Harada, N; Higuchi, N; Kato, M; Kohjima, M; Kotoh, K; Machida, K; Maehara, Y; Matsunaga, K; Nakamuta, M; Nakashima, M; Nishinakagawa, T; Taketomi, A; Yada, M; Yada, R; Yasutake, K; Yoshimoto, T, 2010
)
2.12
"Bezafibrate has no effect on the incidence of coronary heart disease and of stroke combined but may reduce the incidence of non-fatal coronary events, particularly in those aged <65 years at entry, in whom all coronary events may also be reduced."( Bezafibrate in men with lower extremity arterial disease: randomised controlled trial.
Cook, C; Cooper, J; Meade, T; Zuhrie, R, 2002
)
3.2
"and bezafibrate, which also has a lipid- and fibrinogen-lowering potency, was applied in patients suffering from cerebral multi-infarct dementia and disturbances of the hemorheologic situation."( [Hemorrheology and quality of life in fibrinogen- and lipid-lowering therapy].
Bertha, G; Freidl, W; Kleinert, G; Lechner, H; Schied, G; Walzl, B; Walzl, M, 1993
)
0.77
"Bezafibrate has effects on lipid metabolism and haemostatic function. "( Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
de Faire, U; Ericsson, CG; Grip, L; Hamsten, A; Nilsson, J; Svane, B, 1996
)
2.01
"Bezafibrate has anti-inflammatory effects in these patients."( Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.
Jonkers, IJ; Mohrschladt, MF; Smelt, AH; van der Laarse, A; Westendorp, RG, 2002
)
1.25
"Bezafibrate has been proved to be effective in the treatment of hyperlipidaemia in type 2 diabetic patients."( Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia.
Branchi, A; Fasoli, A; Gandini, R; Maraffi, F; Montalto, C; Rovellini, A; Sommariva, D, 1992
)
1.31

Actions

Bezafibrate users had a lower hazard for incident diabetes than users of other fibrates (HR 0.66 [95% CI 0.53-0.81]). Bezafibrate could increase bone mass in intact male rats principally through increasing periosteal bone formation.

ExcerptReferenceRelevance
"Bezafibrate users had a lower hazard for incident diabetes than users of other fibrates (HR 0.66 [95% CI 0.53-0.81]). "( Antidiabetic action of bezafibrate in a large observational database.
Ellenberg, S; Flory, JH; Hennessy, S; Strom, BL; Szapary, PO, 2009
)
2.11
"Bezafibrate could increase bone mass in intact male rats principally through increasing periosteal bone formation."( Bezafibrate prevents palmitate-induced apoptosis in osteoblastic MC3T3-E1 cells through the NF-κB signaling pathway.
Li, Y; Liu, Y; Pan, T; Su, L; Wei, G; Xiao, H; Xiu, L; Zhong, X, 2011
)
2.53
"Bezafibrate-induced increase in CPT II activity also tended to restore the downregulated ATP levels, though moderately, and improved mitochondrial membrane potential even at 41°C to the levels at 37°C in fibroblasts of IAE patients."( Bezafibrate upregulates carnitine palmitoyltransferase II expression and promotes mitochondrial energy crisis dissipation in fibroblasts of patients with influenza-associated encephalopathy.
Chida, J; Kido, H; Yamaguchi, M; Yao, D; Yao, M, 2011
)
2.53
"The bezafibrate-induced increase in large HDL3 (HDL3a) could not be explained solely by its suppression of LCAT and CETP activities."( Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia.
Homma, Y; Kobayashi, T; Mikami, Y; Nakamura, H; Ozawa, H; Sakane, H; Yamaguchi, H, 1994
)
1.16
"Bezafibrate is used to lower serum lipid levels in humans. "( Effects of bezafibrate on ethanol oxidation in rats.
Hirose, M; Isobe, E; Kanegae, T; Nagoya, T; Shimamura, M; Tsukamoto, S, 1996
)
2.13
"Bezafibrate caused an increase in 8-isoprostaglandin F(2alpha) (762+/-313 versus 552+/-245 ng/24 h for bezafibrate and placebo therapy, respectively; P=0.03), whereas 2,3-dinor-5, 6-dihydro-8-isoprostaglandin F(2alpha) levels tended to be increased (1714+/-761 versus 1475+/-606 ng/24 h for bezafibrate and placebo therapy, respectively; P=0.11)."( Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia: effects of bezafibrate therapy.
Buytenhek, R; de Man, FH; Jonkers, IJ; Leuven, JA; Onkenhout, W; Princen, HM; Schwedhelm, E; Smelt, AH; Troost, R; van Der Laarse, A; van Duyvenvoorde, W, 2000
)
1.24

Treatment

Bezafibrate treatment was associated with a reduction in lymphocyte release of interleukin-2, interferon-γ and tumor necrosis factor-α. The treatment significantly reduced serum triglyceride, total cholesterol, and free fatty acids levels and significantly increased the pancreatic wet weight.

ExcerptReferenceRelevance
"Bezafibrate pre-treatment prevented the reduction of GPx, GR, GST and G6PDH activities."( Bezafibrate prevents mitochondrial dysfunction, antioxidant system disturbance, glial reactivity and neuronal damage induced by sulfite administration in striatum of rats: Implications for a possible therapeutic strategy for sulfite oxidase deficiency.
August, PM; Cardoso, GMF; Grings, M; Leipnitz, G; Matté, C; Moura, AP; Parmeggiani, B; Pletsch, JT; Wajner, M; Wyse, ATS, 2017
)
2.62
"Bezafibrate treatment led to a reduction in leukocyte adherence, improved functional capillary density (FCD), and a reduction in interleukin-1α (IL-1α), tumour necrosis factor α (TNF-α) and granulocyte macrophage colony stimulating factors (GM-CSF) plasma levels in experimental sepsis."( Impact of lipid modulation on the intestinal microcirculation in experimental sepsis.
Haußmann-Vopel, S; Lehmann, C; Pavlovic, D; Wegner, A, 2018
)
1.2
"Bezafibrate treatment ameliorates arterial stiffness accompanied by improvement of glycolipid metabolism and oxidative stress. "( Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus.
Imamura, H; Kawana, H; Nagayama, D; Nakamura, S; Ohira, M; Oka, R; Saiki, A; Sato, Y; Shimizu, N; Shirai, K; Tanaka, S; Tatsuno, I; Watanabe, Y; Yamaguchi, T, 2019
)
3.4
"Bezafibrate treatment is associated with reduced risk of cancer among patients with CAD. "( Association of Bezafibrate Treatment With Reduced Risk of Cancer in Patients With Coronary Artery Disease.
Brenner, R; Gerber, Y; Goldenberg, I; Hasin, T; Iakobishvili, Z; Klempfner, R; Kornowski, R; Shlomo, N, 2019
)
2.31
"Bezafibrate treatment prevented islet hypertrophy and reduced body mass, plasma insulin levels, and homeostasis model of assessment for insulin resistance index."( Adverse association between obesity and menopause in mice treated with bezafibrate, a pan peroxisome proliferator-activated receptor agonist.
Aguila, MB; Correia, AL; dos Anjos, TL; Faria, Tda S; Mandarim-de-Lacerda, CA, 2013
)
1.34
"Bezafibrate treatment reduces body mass, plasma insulin levels, and pancreatic islet hypertrophy in mice fed HF."( Adverse association between obesity and menopause in mice treated with bezafibrate, a pan peroxisome proliferator-activated receptor agonist.
Aguila, MB; Correia, AL; dos Anjos, TL; Faria, Tda S; Mandarim-de-Lacerda, CA, 2013
)
1.34
"Bezafibrate treatment resulted in a significant decrease in AP as early as 3 months."( Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.
Bruguera, M; Lens, S; Leoz, M; Nazal, L; Parés, A, 2014
)
2.57
"Bezafibrate treatment increased the mRNA expression levels of fatty acid oxidation-related genes, which are targets of PPAR , and enhanced CO2 production from [14C]-palmitic acid."( Activation of peroxisome proliferator-activated receptor-α (PPARα) in proximal intestine improves postprandial lipidemia in obese diabetic KK-Ay mice.
Goto, T; Kawada, T; Kimura, R; Murota, K; Takahashi, N,
)
0.85
"Bezafibrate treatment restored the impaired PPARγ, PPARδ, PGC-1α signaling pathway, enhanced mitochondrial biogenesis and improved antioxidant defense in the striatum of BACHD mice."( Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.
Beal, MF; Calingasan, NY; Chandra, A; Johri, A; Sharma, A; Shurubor, Y; White, JM; Yang, XW, 2016
)
1.16
"Bezafibrate treatment also increased the EEG delta-power in nonrapid eye movement sleep compared with the control diet attenuating its daily amplitude."( Bezafibrate, a peroxisome proliferator-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice.
Chikahisa, S; Ishida, N; Kawai, T; Kitaoka, K; Oishi, K; Rokutan, K; Séi, H; Tominaga, K, 2008
)
2.51
"Bezafibrate treatment favorably affected pruritus, dyslipidemia, and cholestasis in PFIC-1."( Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis.
Hirano, K; Inomata, Y; Kobayashi, K; Miida, T; Nagasaka, H; Ota, A; Takatani, T; Takayanagi, M; Toyama-Nakagawa, Y; Tsukahara, H; Uemoto, S; Yorifuji, T, 2009
)
1.46
"Bezafibrate treatment was a safe treatment and reduced fibrinogen levels in patients with STEAMI and hyperfibrinogenemia. "( Ipact of bezafibrate treatment in patients with hyperfibrinogenemia and ST-elevation acute myocardial infarction: a randomized clinical trial.
Almeida-Gutiérrez, E; Borrayo-Sánchez, G; Jáuregui-Aguilar, R; Madrid-Miller, A; Martínez-Gómez, DF; Moreno-Ruiz, LA,
)
1.99
"Bezafibrate treatment normalized monocyte release of MCP-1, interleukin-6, TNF-α, and interleukin-1β and also normalized plasma hsCRP levels in mixed dyslipidemic subjects, whereas in IFG individuals the drug reduced only MCP-1 and interleukin-6 release."( Effect of bezafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucose.
Krysiak, R; Okopien, B, 2011
)
1.49
"Bezafibrate treatment enhanced FA oxidation in isolated adipocytes, suppressing adipocyte hypertrophy."( Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes.
Goto, T; Hirai, S; Inoue, H; Kawada, T; Kim, YI; Lee, JY; Takahashi, N; Teraminami, A; Uemura, T, 2011
)
1.09
"Bezafibrate treatment was associated with a reduction in lymphocyte release of interleukin-2, interferon-γ and tumor necrosis factor-α, which was accompanied by a reduction in plasma hsCRP levels."( The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia.
Gdula-Dymek, A; Krysiak, R; Okopien, B, 2011
)
1.45
"Bezafibrate treatment rescued inhibition of follicle development, secretion of E2, and ovulation rate by TNF."( Bezafibrate restores the inhibition of FSH-induced follicular development and steroidogenesis by tumor necrosis factor-alpha through peroxisome proliferator-activated receptor-gamma pathway in an in vitro mouse preantral follicle culture.
Amita, M; Hara, S; Igarashi, H; Kurachi, H; Takahashi, T; Tsutsumi, S, 2011
)
2.53
"Bezafibrate treatment prevented conversion of type I oxidative to type II glycolytic muscle fibers and increased the numbers of muscle mitochondria."( Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.
Beal, MF; Calingasan, NY; Chandra, A; Hennessey, TM; Johri, A; Sharma, A; Wille, E; Yang, L, 2012
)
1.1
"Bezafibrate treatment significantly decreased tau hyperphosphorylation using AT8 staining and the number of MC1-positive neurons."( Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice.
Beal, MF; Calingasan, NY; Chan, RB; Di Paolo, G; Dumont, M; Elipenahli, C; Gerges, M; Jainuddin, S; Pujol, A; Stack, C; Starkov, AA; Starkova, N; Tampellini, D; Yang, L, 2012
)
2.54
"Bezafibrate treatment for at least 4 months markedly increased interferon-γ expression compared with the treatment-naive patients (4.81 vs."( Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C.
Berg, T; Bergk, A; Frost, N; Kintscher, U; Knop, V; Schlosser, B; Thieringer, J; van Bömmel, F, 2013
)
2.55
"Bezafibrate treatment significantly reduced serum triglyceride, total cholesterol, and free fatty acids levels and significantly increased the pancreatic wet weight (1,145 +/- 54 vs 874 +/- 33 mg/rat, p < 0.01), and protein (169 +/- 7 vs 128 +/- 11 mg/pancreas p < 0.01) and enzyme contents in the pancreas compared with those in untreated control rats. "( Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats.
Jia, D; Otsuki, M, 2003
)
3.2
"Bezafibrate treatment reduced secondary end points only in patients with NFG (P =.04)."( High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
Arcavi, L; Behar, S; Boyko, V; Caspi, A; Knobler, H; Reshef, N, 2004
)
1.25
"The bezafibrate-treated groups of OLETF and their control counterpart Long-Evans Tokushima Otsuka (LETO) rats received a bezafibrate-rich diet (150 mg/100 g normal chow) for 16 weeks, from 12 to 28 weeks of age, while the other groups of rats received standard rat chow."( Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats.
Jia, D; Otani, M; Otsuki, M; Yamamoto, M, 2004
)
2.25
"Bezafibrate treatment of LLC-PK1 cells prevented cisplatin-induced translocation of proapoptotic Bax from the cytosol to the mitochondrial fraction, and increased the expression of antiapoptotic molecule Bcl-2."( Fibrate prevents cisplatin-induced proximal tubule cell death.
Bhatt, R; Kaushal, GP; Nagothu, KK; Portilla, D, 2005
)
1.05
"Bezafibrate treatment inhibits cisplatin-mediated tubular injury by preventing the activation of various cellular mechanisms that lead to proximal tubule cell death. "( Fibrate prevents cisplatin-induced proximal tubule cell death.
Bhatt, R; Kaushal, GP; Nagothu, KK; Portilla, D, 2005
)
1.77
"Bezafibrate treatment was associated with significant risk reduction among coronary heart disease patients with elevated triglyceride levels that substantially reduced their triglyceride level with treatment."( Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy.
Battler, A; Behar, S; Benderly, M; Boyko, V; Goldbourt, U; Goldenberg, I; Haim, M; Tanne, D, 2006
)
2.06
"Bezafibrate treatment of mature osteoclast resulted in 50% inhibition (at 10(-8) M and 10(-7) M) of resorption, yet fenofibrate had no significant effect."( PPAR agonists modulate human osteoclast formation and activity in vitro.
Buckley, KA; Chan, BY; Dillon, JP; Fraser, WD; Gallagher, JA; Gartland, A; Wilson, PJ, 2007
)
1.06
"Bezafibrate treatment resulted in significant improvements in LPS-induced dyslipidemia and anorexia, but had no effect on energy expenditure, respiratory quotient, or fasting body weight in the endotoxic rats."( Bezafibrate improves bacterial lipopolysaccharide-induced dyslipidemia and anorexia in rats.
Harada, N; Kusuyama, A; Morishima, M; Nakaya, Y; Okada, K; Takahashi, A, 2007
)
2.5
"Bezafibrate treatment resulted in significant decrease in the serum concentrations of triglycerides, total cholesterol and LDL-cholesterol, whereas HDL-cholesterol serum levels increased."( Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Grützmacher, P; Lang, W; Scheuermann, E, 1981
)
1.26
"Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30% and 37%, respectively."( Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: reduced activity of cholesterol 7 alpha-hydroxylase.
Angelin, B; Berglund, L; Einarsson, K; Reihnér, E; Rudling, M; Ståhlberg, D, 1995
)
1.38
"Bezafibrate treatment resulted in a very pronounced elevation of palmitoyl CoA beta-oxidation in the males but had no similar effect in the females."( Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat.
Amacher, DE; Beck, R; Kenny, CV; Schomaker, SJ, 1997
)
1.22
"Bezafibrate treatment was associated with significantly greater reductions over 3 years in median serum triglyceride (-32 vs. "( Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
Dhanjil, S; Diamond, JR; Elkeles, RS; Feher, MD; Mahmood, S; Mather, H; Nicolaides, AN; Poulter, C; Richmond, W; Sharp, P, 1998
)
1.97
"Bezafibrate treatment at a dose of 400 mg/d for 12 weeks produced an antiatherogenic effect on lipoprotein profiles, as reflected by a decrease in plasma triglyceride levels, an increase in plasma high-density lipoprotein-cholesterol levels, induction of the large-size subclass of low-density lipoprotein, and disappearance of intermediate-density lipoproteins."( Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance.
Hayashi, K; Hiraga, T; Kajiyama, G; Katano, T; Kuga, Y; Kurushima, H; Nomura, K; Ohtani, H; Sakai-Ohta, K; Shingu, T; Tanaka, K; Toyota, Y; Yasunobu, Y, 1998
)
1.32
"Bezafibrate treatment lowered blood pressure, free fatty acids, and triglycerides in the fructose-fed group, suggesting that lipid abnormalities play a role in the elevation of blood pressure in the fructose-induced hypertensive rat."( Bezafibrate, an anti-hypertriglyceridemic drug, attenuates vascular hyperresponsiveness and elevated blood pressure in fructose-induced hypertensive rats.
Richey, JM; Si, X; Webb, RC, 1999
)
2.47
"Bezafibrate treatment resulted in a significant reduction of serum IGF-I levels, both at two and five years, and on-trial serum IGF-I levels were directly related to changes in both minimal lumen diameter (r = 0.25, p < 0.05) and mean segment diameter (r = 0.29, p < 0.05). "( Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.
Båvenholm, P; Brismar, K; de Faire, U; Eféndic, S; Ericsson, CG; Hamsten, A; Nilsson, J; Ruotolo, G, 2000
)
1.94
"With bezafibrate treatment the LDL-cholesterol/LDL-ApoB ratio showed a tendency to rise, suggesting a change in the LDL particle composition to a less small and dense form, while pravastatin treatment induced a decrease in this ratio suggesting a change in the LDL particle to a more dense form."( Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Donker, AJ; Heine, RJ; Hensgens, HE; Rustemeijer, C; Schouten, JA; Voerman, HJ,
)
0.89
"Bezafibrate treatment completely reversed these effects."( Noninvolvement of hypertriglyceridemia and hyperleptinemia in blood pressure increases induced by dietary lard in rats.
Hattori, A; Iguchi, A; Kuzuya, M; Muraguchi, M; Nakamura, J; Ohmoto, Y; Tamaya, N; Ueda, M; Uemura, K; Yoshioka, S, 2001
)
1.03
"Bezafibrate treatment may be a useful adjunct to hypoglycemic therapy in patients with NIDDM."( Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM.
Alberti, KG; Jones, IR; Laker, MF; Miller, M; Swai, A; Taylor, R, 1990
)
1.26
"Bezafibrate treatment did not influence fasting blood glucose concentration, glucose tolerance, peripheral insulin sensitivity or insulin secretion."( Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes.
Capaldo, B; Genovese, S; Mancini, M; Marotta, G; Patti, L; Postiglione, A; Riccardi, G; Rivellese, A; Saldalamacchia, G, 1989
)
1.39
"Treatment with bezafibrate or pioglitazone decreased the α-SMA expression."( Antifibrotic effects of bezafibrate and pioglitazone against thioacetamide-induced liver fibrosis in albino rats.
Abdelrahman, AM; El-Tahawy, NF; Ibrahim, SA; Mohamed, MZ, 2021
)
1.27
"Treatment with bezafibrate (30 or 100mg/kg/day) was performed by gavage during 7days before (pre-treatment) or after sulfite administration."( Bezafibrate prevents mitochondrial dysfunction, antioxidant system disturbance, glial reactivity and neuronal damage induced by sulfite administration in striatum of rats: Implications for a possible therapeutic strategy for sulfite oxidase deficiency.
August, PM; Cardoso, GMF; Grings, M; Leipnitz, G; Matté, C; Moura, AP; Parmeggiani, B; Pletsch, JT; Wajner, M; Wyse, ATS, 2017
)
2.24
"Treatment with bezafibrate for 12 weeks significantly reduced the percentage of circulating CD14(+)CD16(+) monocytes from 45.4 ± 25.2% to 38.3 ± 21.8% (P = 0.0144)."( Bezafibrate, a peroxisome proliferator-activated receptor α agonist, decreases circulating CD14(+)CD16(+) monocytes in patients with type 2 diabetes.
Aso, Y; Fukushima, M; Inukai, T; Momobayashi, A; Omori, K; Terasawa, T, 2015
)
2.2
"Pre-treatment of bezafibrate prevented palmitate-induced NF-κB activation."( Bezafibrate prevents palmitate-induced apoptosis in osteoblastic MC3T3-E1 cells through the NF-κB signaling pathway.
Li, Y; Liu, Y; Pan, T; Su, L; Wei, G; Xiao, H; Xiu, L; Zhong, X, 2011
)
2.14
"Treatment with bezafibrate (n = 20) or atorvastatin (n = 20) for 4 weeks significantly reduced RLP-C levels, with a concomitant improvement in FMD."( Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome.
Fujioka, D; Ichigi, Y; Kawabata, K; Kitta, Y; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K, 2005
)
0.67
"Pretreatment with bezafibrate prevented both the inhibition of PPAR-alpha activity and the accumulation of nonesterified free fatty acids induced by cisplatin."( Fibrate prevents cisplatin-induced proximal tubule cell death.
Bhatt, R; Kaushal, GP; Nagothu, KK; Portilla, D, 2005
)
0.65
"Treatment of bezafibrate caused a marked decrease in the mRNA level of 11beta-HSD1 preferentially in adipose tissue of db/db mice (-47%, P<0.05), concomitant with a significant increase in plasma adiponectin level (+37%, P<0.01)."( Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
Arai, N; Ebihara, K; Hosoda, K; Inada, Y; Ishii, T; Maruyama, K; Masuzaki, H; Nakano, S; Nakao, K; Shibata, N; Tanaka, T; Yamazaki, Y; Yasue, S, 2007
)
2.14
"Treatment with bezafibrate (400 microM for 48 h) resulted in a marked increase in FAO capacities, often leading to restoration of normal values, for 21 genotypes that mainly corresponded to patients with the myopathic phenotype."( Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy.
Andresen, BS; Aubey, F; Bastin, J; Djouadi, F; Fukao, T; Gobin-Limballe, S; Kim, JJ; Mandel, H; McAndrew, R; Olpin, S; Ruiter, JP; Wanders, RJ; Yamaguchi, S, 2007
)
0.9
"Treatment with bezafibrate and micronised fenofibrate both resulted in significant reductions in the serum concentrations of total cholesterol (26.0% and 38.7%), VLDL cholesterol (41.5% and 54.1%) and total triglycerides (27.5% and 39.1%), as well as a significant increase in high density lipoprotein (HDL) cholesterol (15.0% and 27."( Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia.
Feussner, G; Kurth, B; Lohrmann, J, 1997
)
0.95
"Treatment with bezafibrate during 12 weeks reduced serum triglycerides significantly more than simvastatin (-41% vs -22%, p < 0.001) and increased HDL cholesterol more (bezafibrate: + 17% vs simvastatin: + 9%, p < 0.05)."( Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Jeck, T; Keller, U; Riesen, WF, 1997
)
1
"Treatment with bezafibrate decreased VLDL triglycerides and increased HDL cholesterol, but did not affect TNFalpha levels."( Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease.
Båvenholm, P; de Faire, U; Ericsson, CG; Godsland, I; Hamsten, A; Jovinge, S; Nilsson, J; Proudler, A; Tornvall, P, 1998
)
0.64
"Treatment with bezafibrate resulted in an attenuation of the decrease in the weight of epididymal fat and whole body lipid observed in mice following intraperitoneal inoculation of B16."( Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice.
Goto, T; Kawamura, I; Sakai, F; Yamamoto, N; Yamazaki, H,
)
0.74
"Rats treated with bezafibrate, a PPAR activator, gain less body weight and increase daily food intake. "( Bezafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue.
Adzet, T; Alegret, M; Cabrero, A; Laguna, JC; Rodríguez, C; Roglans, N; Sánchez, RM; Vázquez, M, 2001
)
2.09

Toxicity

Bezafibrate in combination with ezetimibe is safe and effective. gemfibrozil appears less effective and more frequently causes adverse effects leading to withdrawal of treatment.

ExcerptReferenceRelevance
" The frequency of clinical adverse experiences was low and similar among treatment groups, the frequency of laboratory adverse experiences was higher in the Lovastatin group."( Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia.
Breier, C; Eber, B; Gaul, G; Klein, W; Schmidt, P; Schumacher, M; Silberbauer, K; Stühlinger, W, 1992
)
0.53
" Safety was assessed from reports of adverse events and by measuring haematological and biochemical parameters."( Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
Betteridge, DJ; O'Bryan-Tear, CG, 1996
)
0.53
" Gemfibrozil treatment was also withdrawn significantly more frequently due to a possible adverse reaction compared with the other two drugs."( A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
Beggs, PW; Clark, DW; Coulter, DM; Williams, SM, 1999
)
0.55
"In normal clinical practice in New Zealand gemfibrozil appears less effective and more frequently causes adverse effects leading to withdrawal of treatment than either bezafibrate or simvastatin."( A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
Beggs, PW; Clark, DW; Coulter, DM; Williams, SM, 1999
)
0.75
" All treatments were well tolerated with no increase in adverse events for combination therapy versus monotherapy, or between combination regimens."( Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study).
Borgnino, C; Mancini, M; Mariani, M; Paoletti, R; Pauciullo, P, 2000
)
0.55
" Adverse events occur more often with the statins that are metabolized via the CYP enzyme system and its 3A4, 2C9 or 2C19 paths."( Lipid-lowering drugs: are adverse effects predictable and reversible?
Muscari, A; Puddu, GM; Puddu, P, 2002
)
0.31
"Rhabdomyolysis is a severe adverse effect of hypolipidaemic agents such as statins and fibrates."( Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis.
Matsuyama, K; Matzno, S; Mishima, M; Nakabayashi, T; Tanaka, H; Tazuya-Murayama, K; Uchida, T; Yasuda, S, 2003
)
0.32
" As a result of its wide use, unmetabolized BZF is released in the environment with potential toxic effects for aquatic living organisms."( Bezafibrate removal by means of ozonation: primary intermediates, kinetics, and toxicity assessment.
Andreozzi, R; Canterino, M; Dantas, RF; Esplugas, S; Marotta, R; Sans, C, 2007
)
1.78
" Fibrates are well tolerated in most cases concomitantly with occasional adverse reactions including muscular toxicity, which is enhanced by the combination with statins."( Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling.
Hashimoto, H; Jomori, T; Okuyama, M; Tagawa, Y; Yang, B; Zhao, Y, 2010
)
1.8
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" The purpose of this case report is to illustrate the clinical and radiological findings of focal myositis as a side effect of statins and fibrates in 2 patients with forearm involvement."( [Focal myositis as a side effect of antilipidemics - 2 patients with involvement of the forearm].
Hohendorff, B; Mühldorfer-Fodor, M; Prommersberger, KJ; Schmitt, R; Wagner, M, 2012
)
0.38
" Safety of the combination was examined in terms of the type, onset, and severity of adverse drug reactions (ADRs)."( Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study.
Abe, K; Taneyama, T; Teramoto, T, 2013
)
0.63
"Bezafibrate in combination with ezetimibe is safe and effective, and is potentially useful for comprehensive management of dyslipidemia."( Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study.
Abe, K; Taneyama, T; Teramoto, T, 2013
)
2.08
" The serum levels of total cholesterol (TC), TG, low-density lipoprotein cholesterol (LDL-C) and HDL-C were assessed before and after 6 and 12 weeks treatment, side effects and adverse events were recorded."( [The lipid-regulating effect and safety of combined statin and bezafibrate therapy in acute coronary syndrome patients complicating with dyslipidemia].
Gong, HR; Huang, WY; Li, XP; Zhao, SP, 2013
)
0.63
"The combined statin and bezafibrate treatment is safe and could increase the ratios of reaching target lipid levels in ACS patients complicating with increased TG and (or) decreased HDL-C."( [The lipid-regulating effect and safety of combined statin and bezafibrate therapy in acute coronary syndrome patients complicating with dyslipidemia].
Gong, HR; Huang, WY; Li, XP; Zhao, SP, 2013
)
0.94
" However, the toxicity of treated water increased, suggesting the generation of toxic oxidation products (OPs)."( Identification of New Oxidation Products of Bezafibrate for Better Understanding of Its Toxicity Evolution and Oxidation Mechanisms during Ozonation.
Gebhardt, W; Lu, S; Schröder, HF; Sui, Q; Yu, G; Zhao, W, 2017
)
0.72
" The most commonly reported adverse events (AEs) were gastrointestinal and musculoskeletal."( Safety of fibrates in cholestatic liver diseases.
Carrion, AF; Levy, C; Lindor, KD, 2021
)
0.62
"Fibrates appear to be safe and well tolerated in patients with PBC, with a low frequency of AEs."( Safety of fibrates in cholestatic liver diseases.
Carrion, AF; Levy, C; Lindor, KD, 2021
)
0.62
"Statins and fibrates are frequently used to treat hyperlipidemia; however, these drugs may have adverse effects such as rhabdomyolysis."( Combination treatment with statins and bezafibrate induces myotoxicity via inhibition of geranylgeranyl pyrophosphate biosynthesis and Rho activation in L6 myoblasts and myotube cells.
Hoshida, T; Kimura, A; Maeda, A; Mastuda, T; Nishida, S; Takeda, T; Tanabe, K; Tsubaki, M; Yanae, M, 2022
)
0.99
" We suggest that Pema may be an effective and safe treatment for hypertriglyceridemia in CKD patients."( Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
Fukuda, H; Iwasaki, M; Koshida, T; Matsuzaki, K; Saito, M; Suzuki, H; Suzuki, Y; Takahara, H; Umezawa, Y, 2023
)
0.91

Pharmacokinetics

Bezafibrate is a new lipid-lowering agent with a more pronounced pharmacological effect, a different metabolism and a much shorter apparent half-life than clofibrate. The pharmacokinetic profile of a 300 mg immediate release formulation was compared to a 400 mg sustained release formulation.

ExcerptReferenceRelevance
" After oral administration of single daily doses for 7 days, the plasma elimination half-life for bezafibrate was rapid (t1/2 of 4-5 h) in comparison to ciprofibrate (t1/2 of 76 h)."( The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat.
Bonner, FW; Eason, CT; Henry, G; Pattison, A; Powles, P; Spencer, AJ, 1989
)
0.74
" The resulting data indicate that the slow-release formulation shows a lower dispersion of Tmax values."( Normal and slow-release formulations of bezafibrate: a comparative pharmacokinetic study in man.
Assereto, R; Castoldi, D; Cunietti, E; Gandini, R; Garanzelli, P; Monzani, W, 1987
)
0.54
"Bezafibrate is a new lipid-lowering agent with a more pronounced pharmacological effect, a different metabolism and a much shorter apparent half-life than clofibrate."( Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
Kaufmann, B; Ledermann, H, 1981
)
1.97
"Comparison of the Pharmacokinetic Profiles of a Quick and a Sustained Release Bezafibrate Formulation/1st Communication: Single-dose application The hypolipaemic agent bezafibrate (CAS 41859-67-0) is available as immediate and sustained release formulation."( [Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration].
Bührens, KG; Gellert, M; Hilgenstock, C; Kühle, K; Reifferscheid, I; Vens-Cappell, B; Winckler, P, 1993
)
0.76
"The pharmacokinetic profile of a 300 mg immediate release formulation (A) was compared to a 400 mg sustained release formulation (B) of the lipid lowering drug bezafibrate (CAS 41859-67-0)."( [Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics].
Berndt, P; Bührens, KG; Hilgenstock, C; Kühle, K; Reifferscheid, I; Schütt, S; Vens-Cappell, B, 1993
)
0.73
" The pharmacokinetic study showed 100% oral bioavailability, good colonic absorption properties and an indication for an enterohepatic cycle."( Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: pharmacodynamic rationale for sustained release preparation of the drug.
Friedman, M; Gilhar, D; Hoffman, A; Lomnicky, Y; Luria, MH, 1999
)
0.58
"The results confirm that BZF has a first pass hepatic pharmacodynamic effect."( Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: pharmacodynamic rationale for sustained release preparation of the drug.
Friedman, M; Gilhar, D; Hoffman, A; Lomnicky, Y; Luria, MH, 1999
)
0.58
" Because a slow-release matrix tablet of the drug combination resulted in a similar magnitude of effect as the IGI administration, the present study provides a pharmacodynamic rationale for the use of a slow-release low-dose niacin-bezafibrate combination."( Pharmacodynamic effects of bezafibrate and niacin combination: implications of the mode of administration.
Friedman, M; Haimov, T; Hoffman, A; Lomnicky, Y; Luria, MH, 2000
)
0.79
" Bezafibrate and fenofibrate had no significant effect on the peak concentration (Cmax) of repaglinide."( Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.
Backman, JT; Kajosaari, LI; Laitila, J; Neuvonen, M; Neuvonen, PJ, 2004
)
1.57
" The method was successfully applied for the evaluation of pharmacokinetic profiles of bezafibrate dispersible tablet in 20 healthy volunteers."( HPLC method for the determination of bezafibrate in human plasma and application to a pharmacokinetic study of bezafibrate dispersible tablet.
Bing-ren, X; Cai-yun, W; Liyan, Y; Teng, W; Wei, Z; Ying, Z,
)
0.63
" The proposed method used for individual drug determinations is applicable for therapeutic monitoring purposes as well as for use in pharmacokinetic investigations."( HPLC determination of bezafibrate in human plasma and its application to pharmacokinetics studies.
Dalmora, SL; de Melo, J; Flores, FC; Hurtado, FK; Poitevin, FS; Rolim, CM; Zimmermann, ES,
)
0.45

Compound-Compound Interactions

Bezafibrate alone or in combination with ursodeoxycholic acid (UDCA) has been used to slow disease progression in patients with primary biliary cholangitis (PBC) Fluvastatin is a new synthetic inhibitor of HMGCoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase.

ExcerptReferenceRelevance
"Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance."( Drug interactions with fibric acids.
Dujovne, CA; Lozada, A, 1994
)
0.29
"Fluvastatin, a new synthetic inhibitor of HMGCoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, has been studied in several models to examine its effects when used in combination with other lipid-modifying agents such as derivatives of fibric acid (bezafibrate), resins (cholestyramine), and niacin."( Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis, LA, 1996
)
0.47
"Fluvastatin, a new synthetic inhibitor of HMGCoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, has been studied in several models to examine its effects when used in combination with other lipid-modifying agents such as derivatives of fibric acid (bezafibrate), resins (cholestyramine), and niacin."( Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis, LA, 1994
)
0.47
"Bezafibrate (BZF) alone or in combination with ursodeoxycholic acid (UDCA) has been used to slow disease progression in patients with primary biliary cholangitis (PBC)."( Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Khakoo, NS; Levy, C; Reynolds, JM; Sultan, S, 2023
)
2.66
"Use of BZF alone or in combination with UDCA improved liver biochemistries in patients with PBC, but its effect on mortality, liver-related complications or quality of life remains unknown."( Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Khakoo, NS; Levy, C; Reynolds, JM; Sultan, S, 2023
)
1.22

Bioavailability

Bezafibrate is a BCS class II drug as it presents very low solubility in water; therefore, its bioavailability after oral administration is very poor. Solubility, release rate, bioavailability in male Sprague Dawley rats, and lipid profile attributes were assessed.

ExcerptReferenceRelevance
" The relative bioavailability based on (C: 1st-Dose-A) ratio of AUC infinity o was within the range 100 +/- 20%."( Comparative pharmacokinetics of two oral bezafibrate preparations.
Cadorniga, R; Gutierrez, JA; Herrero, R; Iglesias, JJ; Molina, IT; Pastoriza, P, 1991
)
0.55
" In the first part of the study the bioavailability of this formulation was compared to the normal preparation of bezafibrate."( Normal and slow-release formulations of bezafibrate: a comparative pharmacokinetic study in man.
Assereto, R; Castoldi, D; Cunietti, E; Gandini, R; Garanzelli, P; Monzani, W, 1987
)
0.75
"h), whereas the bioavailability of A appeared to be higher than that of B when AUEC was corrected for dose (AUEC ratio = 137%)."( [Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration].
Bührens, KG; Gellert, M; Hilgenstock, C; Kühle, K; Reifferscheid, I; Vens-Cappell, B; Winckler, P, 1993
)
0.53
" Relative bioavailability was 105."( HPLC method for the determination of bezafibrate in human plasma and application to a pharmacokinetic study of bezafibrate dispersible tablet.
Bing-ren, X; Cai-yun, W; Liyan, Y; Teng, W; Wei, Z; Ying, Z,
)
0.4
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Bezafibrate is a BCS class II drug as it presents very low solubility in water; therefore, its bioavailability after oral administration is very poor."( Electrosprayed Polymeric Nanospheres for Enhanced Solubility, Dissolution Rate, Oral Bioavailability and Antihyperlipidemic Activity of Bezafibrate.
Anwer, K; Hussain, T; Khan, IU; Mehmood, Y; Mustapha, O; Shafique, S; Shahzad, Y; Shen, C; Sun, R; Yousaf, AM, 2020
)
2.2
" Solubility, release rate, bioavailability in male Sprague Dawley rats, and lipid profile attributes in Wistar rats were assessed in comparison with bezafibrate plain powder."( Electrosprayed Polymeric Nanospheres for Enhanced Solubility, Dissolution Rate, Oral Bioavailability and Antihyperlipidemic Activity of Bezafibrate.
Anwer, K; Hussain, T; Khan, IU; Mehmood, Y; Mustapha, O; Shafique, S; Shahzad, Y; Shen, C; Sun, R; Yousaf, AM, 2020
)
0.96
"5-fold higher oral bioavailability was achieved with the optimized formulation in comparison with bezafibrate plain powder."( Electrosprayed Polymeric Nanospheres for Enhanced Solubility, Dissolution Rate, Oral Bioavailability and Antihyperlipidemic Activity of Bezafibrate.
Anwer, K; Hussain, T; Khan, IU; Mehmood, Y; Mustapha, O; Shafique, S; Shahzad, Y; Shen, C; Sun, R; Yousaf, AM, 2020
)
0.98
"5, w/w/w) might be a capable drug delivery system for orally administering poorly water-soluble bezafibrate with improved bioavailability and antihyperlipidemic effects."( Electrosprayed Polymeric Nanospheres for Enhanced Solubility, Dissolution Rate, Oral Bioavailability and Antihyperlipidemic Activity of Bezafibrate.
Anwer, K; Hussain, T; Khan, IU; Mehmood, Y; Mustapha, O; Shafique, S; Shahzad, Y; Shen, C; Sun, R; Yousaf, AM, 2020
)
0.98

Dosage Studied

Bezafibrate was well-tolerated, but gastro-intestinal side-effects were frequent during therapy with colestyramine. 16 patients tolerated only a reduced dosage of this drug. Significant reductions in serum triglyceride and cholesterol have been achieved after 1 month's therapy with a reduced bezafi dosage.

ExcerptRelevanceReference
" Bezafibrate was administered as a 200 mg dose 3 times daily, while simvastatin dosage ranged from 10 mg to 40 mg once daily at night."( Bezafibrate and simvastatin (MK-733) in the treatment of primary hypercholesterolaemia.
Jankelow, D; Myburgh, DP; Neutel, JM; Smith, DH, 1990
)
2.63
" Bezafibrate was well-tolerated, but gastro-intestinal side-effects were frequent during therapy with colestyramine, and 16 patients tolerated only a reduced dosage of this drug."( Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemia.
Bergmann, S; Fischer, S; Fücker, K; Gehrisch, S; Hanefeld, M; Jaross, W; Lang, PD; Leonhardt, W, 1990
)
1.5
" The effects of different dosing regimens of three hypolipidaemic, peroxisome-proliferator drugs on hepatic enzymes in the Fischer rat following 26 weeks treatment have been studied."( Hepatic induction potency of hypolipidaemic drugs in the rat following long-term administration: influence of different dosing regimens.
Bonner, FW; Gibson, GG; Makowska, JM, 1990
)
0.28
"7%) on probucol reported mild to moderately severe side-effects, mainly gastro-intestinal, but in no case was treatment interrupted, although benzafibrate dosage was temporarily reduced."( Comparative study of bezafibrate and probucol in hyperlipidaemia.
González, G; Páez Moreno, JP, 1989
)
0.6
"2-fold) but not clofibrate or bezafibrate when dosed PO at 50 mg/kg for 2 weeks in cholesterol-fed rats."( Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
Krause, BR; Newton, RS, 1986
)
0.56
" At its recommended dosage of 200 mg 3 times daily, or alternatively 400 mg once daily as a sustained-release preparation, it produces substantial reductions in plasma triglyceride and cholesterol concentrations in patients with hypertriglyceridaemia and hypercholesterolaemia, respectively."( Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.
Monk, JP; Todd, PA, 1987
)
1.72
" Significant reductions in serum triglyceride and cholesterol have been achieved after 1 month's therapy with a reduced dosage of bezafibrate."( The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia.
Baker, F; Walls, J; Williams, AJ, 1984
)
0.77
"Bezalip (bezafibrate), at an oral dosage of 200 mg three times a day, has been used on 12 patients with idiopathic hyperlipidemia, and on 12 patients with hyperlipidemia superimposed with diabetes mellitus."( A therapeutic trial of bezafibrate on patients with hyperlipidemia with or without diabetes mellitus.
Chiang, HL; Chou, TY; Ho, LT; Kwok, CF; Tsai, H, 1984
)
1
" The effects of cholestyramine rapidly disappeared when it was withdrawn from the diet, while the effects of gemfibrozil persisted after dosage was stopped."( Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats.
Maxwell, RE; Nawrocki, JW; Uhlendorf, PD, 1983
)
0.52
" Since the apparent volumes of distribution were in the same range for both drugs, the amount of drug present in the organism in steady-state also differed by a factor of approximately 30 under the usual dosage regimen."( Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
Abshagen, U; Marinow, J; Spörl-Radun, S, 1980
)
0.56
" Adequate dosage in RDT patients was found to be 200mg every 3rd day."( Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Grützmacher, P; Lang, W; Scheuermann, E, 1981
)
0.54
" An individualized dosage of bezafibrate and repeated checks of the serum concentrations of the drug are recommended during long-term treatment of uremic patients."( Treatment of uremic hypertriglyceridaemia with bezafibrate.
Anderson, P; Norbeck, HE, 1982
)
0.81
" Thus, when treating hyperlipoproteinaemia in patients with impaired renal function, the dosage of bezafibrate must be individualized because of its reduced renal elimination."( Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
Anderson, P; Norbeck, HE, 1981
)
0.77
" For the present analysis, we identified 18 patients in the fluvastatin plus bezafibrate group (cohort 1) and 16 patients in the fluvastatin plus cholestyramine group (cohort 2) for whom complete dose-response data were available for the full 56-week duration of all 3 studies."( Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment.
Leitersdorf, E; Muratti, EN; Peters, TK, 1994
)
0.52
" During the study, 28 patients (SG0) received S 10mg; in 14 patients (SG1) dosage was titrated to 20mg and in 18 cases (SG2) to 40mg."( [Reductions in lipid fraction plasma levels induced by simvastatin and bezafibrate. Brazilian multicenter study].
Forti, N, 1993
)
0.52
" Lovastatin 20 mg/day was added to the bezafibrate 600 mg/day regimen for 6 weeks; the lovastatin dosage was then doubled to 40 mg/day for an additional 6 weeks."( Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination.
Abukarshin, R; Elias, N; Lanir, A; Naschitz, JE; Yeshurun, D,
)
0.63
" After an 8-week interval in which a daily dosage of cholestyramine 8 g was added, from baseline, reductions of 26."( Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis, LA, 1996
)
0.29
" Chow-fed rats were orally gavaged daily with a dosing vehicle alone or with 100 mg/kg of each of the fibrates for 1 week and in addition with gemfibrozil for 2 weeks."( Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Auerbach, BJ; Barnett, BC; DeMattos, RB; Essenburg, AD; Haubenwallner, S; Krause, BR; Leff, T; Minton, LL; Newton, RS; Pape, ME, 1995
)
0.29
" The authors report a case of end-stage renal disease in a patient who underwent hemodialysis regularly, taking a reduced dosage of bezafibrate (200 mg/d) for refractory hypertriglyceridemia."( Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD.
Fang, CC; Lee, YT; Su, TC; Yang, KC, 2005
)
0.53
" The dosage of 1-methyl-4-phenyl pyridinium (MPP+) in the striatum by high-performance liquid chromatography indicated that fenofibrate did not affect MPTP metabolism."( Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Bordet, R; Destée, A; Gelé, P; Kreisler, A; Lhermitte, M; Wiart, JF, 2007
)
0.55
" After an 8-week interval in which a daily dosage of cholestyramine 8 g was added, from baseline, reductions of 26."( Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis, LA, 1994
)
0.29
" Age-adjusted incident HF rates were related to elevated baseline inflammatory markers in a dose-response manner."( Inflammation and future risk of symptomatic heart failure in patients with stable coronary artery disease.
Behar, S; Benderly, M; Eisen, A; Goldbourt, U; Haim, M, 2014
)
0.4
" Dogs were treated with bezafibrate once daily, using 200 mg tablets at a dosage of 4-10 mg/kg (depending on body weight)."( Therapy of Canine Hyperlipidemia with Bezafibrate.
Casado, TC; De Marco, V; Florio, JC; Gilor, C; Nakandakare, ER; Noronha, KSM; Santos, EZ, 2017
)
1.03
"Here, we demonstrate detection by mass spectrometry of an intact protein-drug complex directly from liver tissue from rats that had been orally dosed with the drug."( Mass Spectrometry Detection and Imaging of a Non-Covalent Protein-Drug Complex in Tissue from Orally Dosed Rats.
Clayton, B; Cooper, HJ; Dannhorn, A; Goodwin, RJA; Hale, OJ; Hughes, JW; Illes-Toth, E; Jones, S; Rose, J; Sargeant, R; Strittmatter, N, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
monocarboxylic acidAn oxoacid containing a single carboxy group.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (42)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency34.80270.007215.758889.3584AID1224835; AID588342
thioredoxin reductaseRattus norvegicus (Norway rat)Potency28.99000.100020.879379.4328AID488773; AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.02430.006038.004119,952.5996AID1159521
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
farnesoid X nuclear receptorHomo sapiens (human)Potency0.08910.375827.485161.6524AID588527
pregnane X nuclear receptorHomo sapiens (human)Potency70.79460.005428.02631,258.9301AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency51.95360.000229.305416,493.5996AID743069; AID743075
GVesicular stomatitis virusPotency24.54540.01238.964839.8107AID1645842
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency34.66640.001024.504861.6448AID743212; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency17.88050.001019.414170.9645AID743094; AID743140
D(1A) dopamine receptorHomo sapiens (human)Potency6.51270.02245.944922.3872AID488982
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID540317
flap endonuclease 1Homo sapiens (human)Potency3.45340.133725.412989.1251AID588795
survival motor neuron protein isoform dHomo sapiens (human)Potency0.50120.125912.234435.4813AID1458
Interferon betaHomo sapiens (human)Potency24.54540.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency24.54540.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency24.54540.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency24.54540.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)391.00000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)206.25000.11007.190310.0000AID1209455; AID1449628
Fatty acid-binding protein, liverRattus norvegicus (Norway rat)Ki44.40000.01501.24876.9200AID407369
Fatty acid-binding protein, intestinalHomo sapiens (human)Ki33.00000.30005.48149.4000AID407368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 2DHomo sapiens (human)EC50 (µMol)60.00000.02101.27372.8000AID156801
Glutamate receptor ionotropic, NMDA 3BHomo sapiens (human)EC50 (µMol)60.00000.02100.51051.0000AID156801
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)EC50 (µMol)50.00000.00200.47533.2000AID240312
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)EC50 (µMol)73.33330.00001.262610.0000AID141908; AID141913
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)EC50 (µMol)73.33330.00000.764610.0000AID141908; AID141913
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)EC50 (µMol)73.33330.00000.990510.0000AID141908; AID141913
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)EC50 (µMol)73.33330.00001.052810.0000AID141908; AID141913
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)EC50 (µMol)73.33330.00001.160510.0000AID141908; AID141913
Peroxisome proliferator-activated receptor alphaMus musculus (house mouse)EC50 (µMol)90.00000.00021.397110.0000AID141903; AID156453
Peroxisome proliferator-activated receptor deltaMus musculus (house mouse)EC50 (µMol)110.00000.02001.53507.2000AID141908; AID156785
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)67.42500.00000.992210.0000AID156801; AID156802; AID156938; AID1798916; AID223547; AID240313; AID318248; AID320687; AID552196; AID696365; AID736343; AID91246
Peroxisome proliferator-activated receptor gammaMus musculus (house mouse)EC50 (µMol)55.00000.00031.654210.0000AID141913; AID157279
Peroxisome proliferator-activated receptor deltaHomo sapiens (human)EC50 (µMol)45.06800.00020.84609.1000AID156469; AID156611; AID1798916; AID223544; AID318249; AID320688; AID552401; AID696365; AID736342; AID91241
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)EC50 (µMol)60.00000.02100.35851.0000AID156801
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)EC50 (µMol)44.53710.00061.607410.0000AID156123; AID156127; AID156138; AID1700075; AID1798916; AID223541; AID240312; AID318247; AID320686; AID439613; AID552193; AID696365; AID736344; AID91237
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)EC50 (µMol)60.00000.02100.32421.0000AID156801
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)EC50 (µMol)60.00000.02100.51701.0000AID156801
Glutamate receptor ionotropic, NMDA 2CHomo sapiens (human)EC50 (µMol)60.00000.02101.24032.7000AID156801
Glutamate receptor ionotropic, NMDA 3AHomo sapiens (human)EC50 (µMol)60.00000.02100.51051.0000AID156801
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (258)

Processvia Protein(s)Taxonomy
startle responseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
adult locomotory behaviorGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of sensory perception of painGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
cellular response to L-glutamateGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
protein insertion into membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of calcium ion transportGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
calcium ion transmembrane transportGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fatty acid metabolic processFatty acid-binding protein, intestinalHomo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein, intestinalHomo sapiens (human)
intestinal lipid absorptionFatty acid-binding protein, intestinalHomo sapiens (human)
fatty acid transportFatty acid-binding protein, intestinalHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
glucose metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
generation of precursor metabolites and energyPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid beta-oxidationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
apoptotic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
embryo implantationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cholesterol metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell population proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
axon ensheathmentPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid catabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
regulation of skeletal muscle satellite cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid transportPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell-substrate adhesionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to nutrient levelsPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of skeletal muscle tissue regenerationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
keratinocyte proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of myoblast differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
decidualizationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of epithelial cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
keratinocyte migrationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
adipose tissue developmentPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fat cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fat cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
energy homeostasisPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
apoptotic signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
glucose transmembrane transportPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of myoblast proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor deltaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of calcium ion transport into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
propylene metabolic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of membrane potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion homeostasisGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of reactive oxygen species biosynthetic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to glycineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
startle responseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to amphetamineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to xenobiotic stimulusGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sensory perception of painGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
neurogenesisGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sleepGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dopamine metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
serotonin metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of apoptotic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
activation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
negative regulation of dendritic spine maintenanceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
neuromuscular process controlling balanceGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium ion transportGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
dendrite developmentGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
rhythmic processGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
prepulse inhibitionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
negative regulation of dendritic spine developmentGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
calcium ion transmembrane transportGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
modulation of chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (86)

Processvia Protein(s)Taxonomy
glutamate-gated receptor activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
voltage-gated monoatomic cation channel activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
monoatomic cation channel activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
neurotransmitter receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
glutamate receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein, intestinalHomo sapiens (human)
fatty acid bindingFatty acid-binding protein, intestinalHomo sapiens (human)
protein bindingFatty acid-binding protein, intestinalHomo sapiens (human)
long-chain fatty acid bindingFatty acid-binding protein, intestinalHomo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
linoleic acid bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
sequence-specific double-stranded DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calmodulin bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein-containing complex bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
signaling receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
identical protein bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
protein phosphatase 2A bindingGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glutamate receptor activityGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (58)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
presynaptic active zone membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
hippocampal mossy fiber to CA3 synapseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
neuronal cell bodyGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 3BHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cytosolFatty acid-binding protein, intestinalHomo sapiens (human)
microvillusFatty acid-binding protein, intestinalHomo sapiens (human)
apical cortexFatty acid-binding protein, intestinalHomo sapiens (human)
cytosolFatty acid-binding protein, intestinalHomo sapiens (human)
nucleusFatty acid-binding protein, intestinalHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaMus musculus (house mouse)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaMus musculus (house mouse)
nucleusPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cytoplasmGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendriteGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic cleftGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
terminal boutonGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmic vesicle membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
lysosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
late endosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cytoskeletonGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
neuronal cell bodyGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
presynapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 3AHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (220)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID222824Compound was tested for change in the total cholesterol after (po) administration of 100 mg/kg in mice2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
A novel series of 2,6,7-substituted 2,3-dihydro-1,4-benzodioxin and 2,6,7-substituted 1,4-benzodioxin derivatives as lipid peroxidation inhibitors. Structure-activity relationships for high inhibition of human low-density lipoprotein peroxidation.
AID157279Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID238856Binding affinity for human peroxisome proliferator activated receptor alpha2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID188706In vivo percent reduction on TG of the rat at 30 mg/kg after 5 days2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
AID204503Maximum achieved Nonfasted triglycerides reduction relative to vehicle treated control group2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID156127Transactivation of human Peroxisome proliferator activated receptor alpha expressed in CHO-K1 cells2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARalpha-selective activators.
AID736340Cytotoxicity against human HEK293 cells assessed as cell viability at 10 uM measured after 48 hrs by MTS assay relative to vehicle control2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID736345Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as beta-galactosidase activity at 25 uM measured after 48 hrs relative to vehicle control2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID320686Agonist activity at human PPARalpha expressed in CV1 cells by transactivation assay2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
AID156138In vitro effective concentration for agonist activity on human Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected KRP-297 cells2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID231857Evaluated for antisickling activity, and ratio was calculated as solubility HbS (g/dL) / solubility HbS control(g/dL) at a concentration of 20 mM1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site.
AID156123Compound was tested for agonist activity on human Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CV-1 cells1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID185029Minimum effective dose producing a 40-60% decrease in serum TLDL cholesterol in rats relative to vehicle -treated controls1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID696365Transactivation of PPAR transfected in human HepG2 cells after 20 hrs by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Diarylheptanoid glycosides from Tacca plantaginea and their effects on NF-κB activation and PPAR transcriptional activity.
AID439612Antagonist activity at human T1R2/T1R3 receptor expressed in HEK293E cells assessed as inhibition of sucralose-induced intracellular calcium mobilization2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.
AID318249Agonist activity at human PPARdelta expressed in monkey CV1 cells by transactivation assay2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
AID223546Fold activation relative to maximum activation obtained with carbacyclin2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID226490Oxygen pressure in mmHg at which the control hemoglobin solution (in presence of 10 mM compound) was 50% saturated with oxygen.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID736339Cytotoxicity against human HEK293 cells assessed as cell viability at 100 uM measured after 48 hrs by MTS assay relative to vehicle control2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID22149Solubility ratio ([HbS+drug (5 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID92894Ability of 0.5 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in intact red cells1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID552401Agonist activity at human PPARdelta expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
AID231859Evaluated for antisickling activity, and ratio was calculated as solubility HbS compound (g/dL) / solubility HbS control(g/dL) at a concentration of 40 mM1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID22013Solubility ratio ([HbS+drug (20 mM)]/[HbS-drug]1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID188694In vivo percent reduction on FFA of the rat at 30 mg/kg after 5 days2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
AID1846360Induction of glucose-stimulated insulin secretion in rat INS-1 832/13 cells incubated for 5 mins by ELISA assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID91241Agonist activity for Human PPAR delta receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID320688Agonist activity at human PPARdelta expressed in CV1 cells by transactivation assay2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID226489Oxygen pressure in mmHg at which the control hemoglobin solution (no compound) was 50% saturated with oxygen.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
AID736341Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as beta-galactosidase activity at 50 uM measured after 48 hrs relative to vehicle control2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID204504Maximum achieved Total cholesterol reduction relative to vehicle treated control group2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID240312Effective concentration against human peroxisome proliferator activated receptor alpha in Gal4 transactivation assay2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID223543Fold activation relative to maximum hPPAR alpha activation obtained with WY-146432002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID231976Ratio of effect of compound on affinity of hemoglobin for oxygen to that of control1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID439613Activity at PPARalpha2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1221821Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 1 mM measured at 24 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID21143Solubility of Deoxyhemoglobin S (dHbS) concentration after addition dithionite as control1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID141903Agonist activity for murine PPAR alpha receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID21145Solubility of Haemoglobin S (HbS) concentration after addition of acid and dithionite1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID223549Fold activation relative to maximum activation obtained with rosiglitazone2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID22012Solubility ratio ([HbS+drug (10 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID1665608AUC (0.5 to 6 hrs) in C57BL/6 mouse brain at 9.14 umol/kg, ip by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
AID156801Compound was tested for agonist activity on human Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID141913Agonist activity for murine PPAR gamma receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID221789Ability of 0.5 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in membrane free hemoglobin solution1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID736343Agonist activity at human PPARgamma expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID1665619AUC (0.5 to 6 hrs) in C57BL/6 mouse serum at 9.14 umol/kg, ip by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
AID420697Reduction of plasma triglyceride level in human2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
AID156802Concentration of compound that affords half-maximum transactivation of human Peroxisome proliferator activated receptor gamma in CHO-K1 cells was determined in vitro2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARalpha-selective activators.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID318247Agonist activity at human PPARalpha expressed in monkey CV1 cells by transactivation assay2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID156469Compound was tested for agonist activity on human Peroxisome proliferator activated receptor delta-GAL4 chimeric receptor in transfected CV-1 cells1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID683657Hypolipidemic activity in Swiss albino mouse assessed as reduction in plasma triglyceride level at 50 mg/kg, po for 8 days measured on day 9 by spectrophotometry relative to control2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological evaluation of ester prodrugs of Benzafibrate as orally active hypolipidemic agents.
AID223547In vitro transactivation using receptor transactivation assay against hPPAR gamma2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID223544In vitro transcriptional activation of hPPAR delta2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID223541In vitro transactivation using receptor transactivation assay against hPPAR alpha2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1665630Brain to serum concentration ratio, Kp of the compound in C57BL/6 mouse at 9.14 umol/kg, ip by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID204502Effective dose which produces the desired total cholesterol levels imale Sprgue-Dawley rats.2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID1700074Agonist activity at GAL4-tagged PPARalpha-LBD (unknown origin) expressed in HEK293 cells assessed as induction of receptor transactivation at 1 uM incubated for 16 hrs by luciferase reporter gene assay relative to GW7647
AID231856Evaluated for antisickling activity, and ratio was calculated as solubility HbS (g/dL) / solubility HbS control(g/dL) at a concentration of 10 mM1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site.
AID156611Agonist activity on Gal4 chimeric human Peroxisome proliferator activated receptor delta expressed in CHO-K1 cells2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
AID1700076Toxicity in HEK293 cells assessed as effect on ATP content at 0.1 uM to 10000 uM
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID407368Displacement of 1-anilinonaphthalene-8-sulphonic acid from I-FABP2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID156453Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor transfected CV-1 cells1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID188700In vivo percent reduction on LDL+VLDL of the rat at 30 mg/kg after 5 days2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
AID141908Agonist activity for murine PPAR delta receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID736342Agonist activity at human PPARdelta expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID238857Binding affinity for human peroxisome proliferator activated receptor gamma2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID240313Effective concentration against human peroxisome proliferator activated receptor gamma in Gal4 transactivation assay2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID85637Control value of dHbS(no. of runs=3)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site.
AID318248Agonist activity at human PPARgamma expressed in monkey CV1 cells by transactivation assay2008Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID320687Agonist activity at human PPARgamma expressed in CV1 cells by transactivation assay2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
AID231858Evaluated for antisickling activity, and ratio was calculated as solubility HbS (g/dL) / solubility HbS control(g/dL) at a concentration of 5 mM1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site.
AID204501Effective dose which produces the desired nonfasting triglyceride levels in high cholesterol fed male Sprgue-Dawley rats.2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID22148Solubility ratio ([HbS+drug (40 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID683651Octanol-phosphate buffer partition coefficient, log P of the compound at pH 7.4 by HPLC analysis2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological evaluation of ester prodrugs of Benzafibrate as orally active hypolipidemic agents.
AID85632Compound was evaluated for antisickling activity, and initial HbS concentration was reported, values from different experiments (no. of runs=3)1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site.
AID427202Binding affinity to rat recombinant L-FABP high affinity site expressed in Escherichia coli BL21(DE3) assessed as occupancy at a drug-protein molar ratio of 3:1 by NMR chemical shift perturbation method2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID221790Ability of 1 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in membrane free hemoglobin solution1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID407369Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP low binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID93014Ability of 1 mM to reduce affinity of hemoglobin for oxygen is assessed from 50% partial pressure of oxygen in intact red cells1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Synthesis and investigation of effects of 2-[4- [[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships.
AID655420Transactivation of PPAR expressed in HepG2 cells after 20 hrs by luminescence assay2012Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7
Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID420698Increase of plasma HDL cholesterol level in human2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
AID736344Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID427201Binding affinity to rat recombinant L-FABP low affinity site expressed in Escherichia coli BL21(DE3) assessed as occupancy at a drug-protein molar ratio of 3:1 by NMR chemical shift perturbation method2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Probing the fibrate binding specificity of rat liver fatty acid binding protein.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID188712In vivo percent reduction on total cholesterol of the rat at 30 mg/kg after 5 days2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
AID156938Agonist activity on Gal4 chimeric human Peroxisome proliferator activated receptor gamma expressed in KRP-297 cells2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID222823Compound was tested for change in the LDL-VLDL fraction after (po) administration of 100 mg/kg in mice2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
A novel series of 2,6,7-substituted 2,3-dihydro-1,4-benzodioxin and 2,6,7-substituted 1,4-benzodioxin derivatives as lipid peroxidation inhibitors. Structure-activity relationships for high inhibition of human low-density lipoprotein peroxidation.
AID226491Allosteric activity evaluated as the ratio of the oxygen pressure in mmHg between hemoglobin-compound and compound-free hemoglobin (control) solution at which 50% oxygen saturation's are respectively attained.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin oxygen effectors.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1700075Agonist activity at GAL4-tagged PPARalpha-LBD (unknown origin) expressed in HEK293 cells assessed as induction of receptor transactivation incubated for 16 hrs by luciferase reporter gene assay
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID552196Agonist activity at human PPARgamma expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
AID552193Agonist activity at human PPARalpha expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity after 20 to 22 hrs by luciferase based transactivation assay2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
AID91246Agonist activity for Human PPAR gamma receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID683658Hypolipidemic activity in Swiss albino mouse assessed as reduction in plasma total cholesterol level at 50 mg/kg, po for 8 days measured on day 9 by spectrophotometry relative to control2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological evaluation of ester prodrugs of Benzafibrate as orally active hypolipidemic agents.
AID156785Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor delta-GAL4 chimeric receptor in transfected CV-1 cells1999Journal of medicinal chemistry, Sep-23, Volume: 42, Issue:19
A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
AID91237Agonist activity for Human PPAR alpha receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346733Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)2002Biochemical and biophysical research communications, Jan-11, Volume: 290, Issue:1
Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.
AID1346733Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)2004Journal of medicinal chemistry, Aug-12, Volume: 47, Issue:17
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1798916Cell-Based Transcription Assay from Article 10.1021/jm058056x: \\Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.\\2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.
AID1802450Oatp1d1 Transport Assay from Article 10.1074/jbc.M113.518506: \\Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.\\2013The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,271)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990211 (16.60)18.7374
1990's321 (25.26)18.2507
2000's372 (29.27)29.6817
2010's290 (22.82)24.3611
2020's77 (6.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.37 (24.57)
Research Supply Index7.38 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index124.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (70.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials267 (20.00%)5.53%
Reviews122 (9.14%)6.00%
Case Studies104 (7.79%)4.05%
Observational4 (0.30%)0.25%
Other838 (62.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, Parallel Group, Multicenter Study to Evaluate the Effect of Praluent® (Alirocumab) on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercho [NCT02984982]Phase 4206 participants (Actual)Interventional2016-11-15Completed
Effect of Bezafibrate on Very Long Chain Fatty Acid Metabolism in Men With X-linked Adrenoleukodystrophy (X-ALD) [NCT01165060]10 participants (Anticipated)Interventional2010-07-31Completed
Eryngium Heterophyllum + Amphipterygium Adstringens Tea Effect on Triglyceride Levels [NCT03649269]34 participants (Actual)Interventional2014-01-01Completed
Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction [NCT02291796]Phase 4100 participants (Actual)Interventional2011-01-31Completed
Evaluation of Haematological Improvement in Patients With Low-risk MDS by Comparing VBaP With Danazol in Patients Who Have Either Received Erythropoiesis Stimulating Agents (ESA) and Lost Response, Not Responded to ESA or Are Deemed Unlikely to Respond to [NCT04997811]Phase 2120 participants (Anticipated)Interventional2021-12-21Recruiting
A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis [NCT05239468]Phase 260 participants (Anticipated)Interventional2022-03-21Active, not recruiting
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination With Bezafibrate in Subjects With Primary Biliary Cholangitis Who Had an Inadequate Response or Who [NCT04594694]Phase 272 participants (Anticipated)Interventional2019-10-02Active, not recruiting
Multicenter, Randomized, Double-blind Placebo Controlled Trial of Bezafibrate for the Treatment of Primary Biliary Cirrhosis in Patients With Incomplete Response to Ursodesoxycholic Acid Therapy. [NCT01654731]Phase 3100 participants (Actual)Interventional2012-10-15Completed
The Effect of Bezafibrate on Cholestatic Itch [NCT02701166]Phase 384 participants (Anticipated)Interventional2016-02-29Recruiting
Study of Efficacy of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy [NCT04561466]Phase 2/Phase 314 participants (Actual)Interventional2019-03-26Completed
Evaluation of the Effect of Bezafibrate on Muscle Metabolism During Exercise in Patients With CPTII and VLCAD Deficiency [NCT00983788]Phase 212 participants (Actual)Interventional2009-10-31Completed
Double Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy [NCT04309773]Phase 3104 participants (Anticipated)Interventional2021-04-06Recruiting
Clinical Trial on the Effect of Bezafibrate in the Muscular Form of Carnitine Palmitoyltransferase 2 Deficiency [NCT00336167]Phase 312 participants Interventional2006-06-30Recruiting
A Randomized, Multi-Center Study to Compare the Effects of CRx-401 to Bezafibrate Plus Placebo on Plasma Glucose Levels When Given to Subjects With Type II Diabetes on Metformin. [NCT00506298]Phase 2150 participants (Anticipated)Interventional2007-07-31Completed
Efficacy and Security of Bezafibrate in Patients With Primary Biliary Cirrhosis Without Biochemical Response to Ursodeoxycholic Acid: A Randomized, Double-blind, Placebo-controlled Trial [NCT02937012]Phase 334 participants (Anticipated)Interventional2016-10-31Recruiting
A Pan-PPAR Agonist Treatment for Bipolar Depression: A Proof of Concept Study [NCT02481245]Phase 230 participants (Anticipated)Interventional2015-09-30Recruiting
Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients With Mixed Dyslipidemia: A Pilot Clinical Trial [NCT02548832]Phase 336 participants (Actual)Interventional2013-04-30Completed
A Feasibility Study of Bezafibrate in Mitochondrial Myopathy [NCT02398201]Phase 26 participants (Actual)Interventional2015-09-30Completed
Safety and Efficacy of Bezafibrate Plus Ursodesoxicolic Acid in Patients With Primary Biliary Cholangitis Without Response [NCT04751188]Phase 311 participants (Anticipated)Interventional2020-10-02Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02548832 (13) [back to overview]Waist Circumference (WC) After 90 Days
NCT02548832 (13) [back to overview]Body Mass Index (BMI) After 90 Days
NCT02548832 (13) [back to overview]Body Weight (BW) After 90 Days
NCT02548832 (13) [back to overview]Creatinine After 90 Days
NCT02548832 (13) [back to overview]Diastolic Blood Pressure After 90 Days
NCT02548832 (13) [back to overview]Fasting Serum Glucose (FSG) After 90 Days
NCT02548832 (13) [back to overview]High Density Lipoprotein Cholesterol (HDL-c) After 90 Days
NCT02548832 (13) [back to overview]Low Density Lipoprotein Cholesterol (LDL-c) After 90 Days
NCT02548832 (13) [back to overview]Systolic Blood Pressure After 90 Days
NCT02548832 (13) [back to overview]Total Cholesterol After 90 Days.
NCT02548832 (13) [back to overview]Triglycerides After 90 Days
NCT02548832 (13) [back to overview]Uric Acid After 90 Days
NCT02548832 (13) [back to overview]Very Low Density Lipoprotein After 90 Days
NCT02984982 (24) [back to overview]Percent Change From Baseline in External Elastic Membrane Volume at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Fasting Triglycerides at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in High-density Lipoprotein Cholesterol at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Lipoprotein (a) at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Lumen Volume at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Total Cholesterol at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36
NCT02984982 (24) [back to overview]Number of Participants With Cardiovascular (CV) Adverse Events
NCT02984982 (24) [back to overview]Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Lumen Volume at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Normalized Total Atheroma Volume at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36
NCT02984982 (24) [back to overview]Absolute Change From Baseline in Total Cholesterol (TC) at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Apolipoprotein A-1 at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Apolipoprotein B at Week 36
NCT02984982 (24) [back to overview]Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36

Waist Circumference (WC) After 90 Days

The waist circumference was evaluated at baseline and after 90 days after an overnight fast with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters. (NCT02548832)
Timeframe: 90 days

Interventioncm (Mean)
Berberine94.0
Bezafibrate98.0
Berberine Plus Bezafibrate88.7

[back to top]

Body Mass Index (BMI) After 90 Days

The BMI was calculated at baseline and after 90 days by the square of the body height, and is universally expressed in units of kg/m^2, resulting from mass in kilograms and height in metres. (NCT02548832)
Timeframe: 90 days

Interventionkg/m^2 (Mean)
Berberine29.6
Bezafibrate31.8
Berberine Plus Bezafibrate28.4

[back to top]

Body Weight (BW) After 90 Days

The body weight was evaluated at baseline and after 90 days after an overnight fast, through a bioimpedance digital scale results are reported in kilograms with a decimal. (NCT02548832)
Timeframe: 90 days

Interventionkg (Mean)
Berberine75.4
Bezafibrate83.6
Berberine Plus Bezafibrate73.0

[back to top]

Creatinine After 90 Days

The blood sample for the determination of creatinine was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method. (NCT02548832)
Timeframe: 90 days

InterventionmM (Mean)
Berberine53.0
Bezafibrate44.2
Berberine Plus Bezafibrate61.9

[back to top]

Diastolic Blood Pressure After 90 Days

The diastolic blood pressure was evaluated at baseline and after 90 days with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of DBP. The value was expressed on mmHg. (NCT02548832)
Timeframe: 90 days

InterventionmmHg (Mean)
Berberine73
Bezafibrate74
Berberine Plus Bezafibrate72

[back to top]

Fasting Serum Glucose (FSG) After 90 Days

The glucose oxidase technique (Beckman Instruments, Inc., Brea, California, USA) was used to determine fasting serum glucose at baseline and after 90 days with an intra- and interassay coefficient of variation of <1. (NCT02548832)
Timeframe: 90 days

InterventionmM (Mean)
Berberine5.6
Bezafibrate5.5
Berberine Plus Bezafibrate5.3

[back to top]

High Density Lipoprotein Cholesterol (HDL-c) After 90 Days

The blood sample for the determination of high density lipoprotein cholesterol was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method. (NCT02548832)
Timeframe: 90 days

InterventionmM (Mean)
Berberine1.5
Bezafibrate2.0
Berberine Plus Bezafibrate1.8

[back to top]

Low Density Lipoprotein Cholesterol (LDL-c) After 90 Days

The blood sample for the determination of low density lipoprotein cholesterol was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method. (NCT02548832)
Timeframe: 90 days

InterventionmM (Mean)
Berberine2.8
Bezafibrate2.4
Berberine Plus Bezafibrate2.2

[back to top]

Systolic Blood Pressure After 90 Days

The systolic blood pressure was evaluated at baseline and after 90 days with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of SBP. The value was expressed on mmHg. (NCT02548832)
Timeframe: 90 days

InterventionmmHg (Mean)
Berberine122
Bezafibrate122
Berberine Plus Bezafibrate114

[back to top]

Total Cholesterol After 90 Days.

The blood sample for the determination of total cholesterol was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method. (NCT02548832)
Timeframe: 90 days

InterventionmM (Mean)
Berberine5.3
Bezafibrate5.8
Berberine Plus Bezafibrate4.6

[back to top]

Triglycerides After 90 Days

The blood sample for the determination of triglycerides was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method. (NCT02548832)
Timeframe: 90 days

Interventionmmol/L (Mean)
Berberine2.3
Bezafibrate1.1
Berberine Plus Bezafibrate1.3

[back to top]

Uric Acid After 90 Days

The blood sample for the determination of uric acid was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method. (NCT02548832)
Timeframe: 90 days

InterventionmM (Mean)
Berberine Baseline285.5
Bezafibrate350.9
Berberine Plus Bezafibrate279.5

[back to top]

Very Low Density Lipoprotein After 90 Days

The blood sample for the determination of VLDL was taken after an overnight fast and was calculated at baseline and after 90 days as triglycerides/5. (NCT02548832)
Timeframe: 90 days

InterventionmM (Mean)
Berberine0.4
Bezafibrate0.2
Berberine Plus Bezafibrate0.2

[back to top]

Percent Change From Baseline in External Elastic Membrane Volume at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and the baseline EEM volume value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Mean)
Standard of Care-0.86
Alirocumab-3.18

[back to top]

Percent Change From Baseline in Fasting Triglycerides at Week 36

Adjusted mean and SE were obtained by multiple imputation approach followed by robust regression model included fixed categorical effect of treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) and the continuous fixed covariate of baseline fasting TGs value. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Mean)
Standard of Care-8.85
Alirocumab-18.37

[back to top]

Percent Change From Baseline in High-density Lipoprotein Cholesterol at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline HDL-C value and baseline HDL-C value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Least Squares Mean)
Standard of Care12.19
Alirocumab21.04

[back to top]

Percent Change From Baseline in Lipoprotein (a) at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effect, and baseline Lp(a) value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Mean)
Standard of Care-17.23
Alirocumab-55.76

[back to top]

Percent Change From Baseline in Lumen Volume at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effect, and the baseline lumen volume value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Mean)
Standard of Care1.20
Alirocumab-0.86

[back to top]

Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 36

Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and baseline Apo A-1 value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Least Squares Mean)
Standard of Care3.8
Alirocumab12.0

[back to top]

Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36

Least-squares (LS) means and standard errors (SE) at Week 36 were obtained from analysis of covariance (ANCOVA) model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and the baseline normalized TAV as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Least Squares Mean)
Standard of Care-3.14
Alirocumab-4.79

[back to top]

Percent Change From Baseline in Total Cholesterol at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline TC value and baseline TC value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Least Squares Mean)
Standard of Care-7.59
Alirocumab-35.43

[back to top]

Absolute Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36

Adjusted LS mean and SE at Week 12 and Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated LDL-C value and baseline calculated LDL-C value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 12, Week 36

,
Interventionmg/dL (Least Squares Mean)
Week 12Week 36
Alirocumab-62.4-63.2
Standard of Care-9.6-15.5

[back to top]

Number of Participants With Cardiovascular (CV) Adverse Events

The suspected or confirmed CV events that occurred from randomization until end of the study visit were collected and reported. The various CV events included CV death, myocardial infarction, ischemic stroke, unstable angina requiring hospitalization , congestive heart failure requiring hospitalization, congestive heart failure requiring hospitalization, ischemia-driven coronary revascularization procedure. (NCT02984982)
Timeframe: Up to 36 weeks

,
InterventionParticipants (Count of Participants)
Cardiovascular deathMyocardial infarctionIschemic strokeUnstable angina requiring hospitalizationCongestive heart failure requiring hospitalizationIschemia led coronary revascularization procedure
Alirocumab022004
Standard of Care030002

[back to top]

Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36

Adjusted LS mean and SE at Week 12 and Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated LDL-C value and baseline calculated LDL-C value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 12, Week 36

,
Interventionpercent change (Least Squares Mean)
Week 12Week 36
Alirocumab-64.53-63.94
Standard of Care-7.57-13.40

[back to top]

Absolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36

Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and baseline Apo B value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Least Squares Mean)
Standard of Care-16.8
Alirocumab-51.0

[back to top]

Absolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model with treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]), as fixed categorical effects, and the baseline EEM volume value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmm^3 (Mean)
Standard of Care-8.23
Alirocumab-10.01

[back to top]

Absolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36

Adjusted mean and SE were obtained from multiple imputation approach followed by robust regression model including fixed categorical effect of treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) and the continuous fixed covariate of baseline fasting TGs value. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Mean)
Standard of Care-26.2
Alirocumab-35.3

[back to top]

Absolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline HDL-C value and baseline HDL-C value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Least Squares Mean)
Standard of Care4.7
Alirocumab8.1

[back to top]

Absolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effect, and baseline Lp(a) value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Mean)
Standard of Care-10.3
Alirocumab-15.5

[back to top]

Absolute Change From Baseline in Lumen Volume at Week 36

Adjusted mean and SE at Week 36 were obtained from robust regression model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and the baseline lumen volume value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmm^3 (Mean)
Standard of Care-1.25
Alirocumab-0.93

[back to top]

Absolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated non-HDL-C value and baseline calculated non-HDL-C value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Least Squares Mean)
Standard of Care-20.3
Alirocumab-69.2

[back to top]

Absolute Change From Baseline in Normalized Total Atheroma Volume at Week 36

LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and the baseline normalized TAV as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventioncubic millimeter (mm^3) (Least Squares Mean)
Standard of Care-4.73
Alirocumab-5.77

[back to top]

Absolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36

LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and the baseline PAV as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent atheroma volume (Least Squares Mean)
Standard of Care-1.28
Alirocumab-1.42

[back to top]

Absolute Change From Baseline in Total Cholesterol (TC) at Week 36

LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated TC value and baseline calculated TC value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionmg/dL (Least Squares Mean)
Standard of Care-15.2
Alirocumab-61.7

[back to top]

Percent Change From Baseline in Apolipoprotein A-1 at Week 36

Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and baseline Apo A-1 value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Least Squares Mean)
Standard of Care4.61
Alirocumab11.75

[back to top]

Percent Change From Baseline in Apolipoprotein B at Week 36

Adjusted LS mean and SE at Week 36 were obtained from ANCOVA model including treatment arm (SoC arm, alirocumab arm) and randomization strata (statin at ACS onset [Yes / No]) as fixed categorical effects, and baseline Apo B value as continuous fixed covariate. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Least Squares Mean)
Standard of Care-16.61
Alirocumab-55.13

[back to top]

Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36

Adjusted LS mean and SE at Week 36 were obtained from mixed-effect model including all available post-baseline data from Week 4 to Week 36. Model included treatment arm (SoC arm, alirocumab arm), randomization strata (statin at ACS onset [Yes / No]), time point, treatment-by-time point and randomization strata-by-time point interaction as fixed categorical effects, and baseline calculated non-HDL-C value and baseline calculated non-HDL-C value-by-time point interaction as continuous fixed covariates. (NCT02984982)
Timeframe: Baseline, Week 36

Interventionpercent change (Least Squares Mean)
Standard of Care-14.06
Alirocumab-54.50

[back to top]